Align Tech AI Stock Analysis
Want to see ALGN full AI Analyst Report?
Align Tech (ALGN) AI Stock Analysis
Align Tech
(NASDAQ:ALGN)
ALGN scores well primarily due to strong underlying financial quality (especially the balance sheet) and a generally upbeat earnings outlook that emphasizes continued growth and margin expansion. Offsetting factors are a mixed technical picture (long-term trend still below major moving averages) and a valuation that is not especially compelling given the ~23x P/E and no dividend yield.
Align Tech Key Performance Indicators (KPIs)
Revenue by SegmentShows how much revenue each business segment generates, highlighting which areas are driving growth and which may need strategic adjustments.
Clear Aligner is the durable growth engine — recovering from the 2022 dip and accelerating through 2025–mid‑2026, signaling resilient case volume/ pricing rather than a one‑off lift. Imaging Systems & CAD/CAM are much smaller and lumpy, driven by device cycles and capex; recent weakness there while aligner revenue rises implies consumable/service demand is outpacing equipment sales. For investors, aligners lower revenue downside and underpin organic growth, but imaging cyclicality limits upside until scanner placements or enterprise deals re‑accelerate.
Align Tech (ALGN) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $11.52B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.01M
- Price to Earnings (P/E)
- 23.7
- Beta (1Y)
- 1.18
- Revenue Growth
- 4.42%
- EPS Growth
- 33.43%
- Country
- US
- Employees
- 20,290
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Align Tech Business Overview & Revenue Model
Company Description
Align Technology, Inc. is a medical technology enterprise that develops, produces, and markets its leading products: Invisalign transparent dental aligners and iTero digital intraoral scanners, along with related services. These offerings serve a wid...
How the Company Makes Money
Align Technology primarily makes money by selling products and services that support clear aligner therapy and digital dentistry workflows. Its largest revenue stream is typically the Clear Aligner segment, where Align sells Invisalign clear aligner...
Align Tech Earnings Call Summary
The call was positive overall. Align reported record Clear Aligner shipments and doctor submitters, broad international growth, improved utilization, stronger operating margins, healthy cash generation and continued investment in digital workflows and 3D-printing innovation. These strengths outweighed the lowlights, which included a challenging consumer environment, lower Systems and Services revenue, ASP and mix pressure, North American GP retail weakness, foreign exchange effects and reduced fourth-quarter revenue assumptions.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For Q4 2026, assuming no circumstances occur beyond our control that could impact our business, Align expects worldwide revenues in the range of $1 billion to $1.020 billion, Clear Aligner volume to be up low single digits year-over-year, Clear Aligner ASP to be down approximately 1% year-over-year, Systems and Services revenue in the range of $170 million to $180 million, GAAP gross margin of approximately 71%, non-GAAP gross margin of approximately 72%, GAAP operating margin of approximately 20%, non-GAAP operating margin of approximately 26%, and to repurchase up to $300 million of common stock; for fiscal 2026, it expects worldwide revenue of approximately $4.11 billion to $4.13 billion, Clear Aligner volume and revenue growth up approximately 5% to 6% year-over-year, Clear Aligner ASP slightly below 2025, Systems and Services revenue of $715 million to $725 million, GAAP operating margin of approximately 16.2%, up approximately 2.7 points year-over-year, non-GAAP operating margin of approximately 23.7%, representing approximately 100 basis point improvement year-over-year, capital expenditures of approximately $125 million to $150 million, and approximately $500 million of common-stock repurchases; for 2027, Align expects another year of revenue growth and margin expansion, continued Invisalign volume growth, record doctor submitters, improving utilization, a broadly stable Clear Aligner pricing environment with ASP slightly down, Systems and Services revenue growth with solid unit growth and stable ASPs, and at least another 100 basis points of non-GAAP operating margin improvement, with preliminary planning assuming an operating environment broadly consistent with current conditions and not requiring a consumer recovery.
Align Tech Financial Statement Overview
Summary
Financials are solid overall, led by an exceptionally conservative balance sheet (very low leverage) and healthy profitability. Recent revenue growth has accelerated sharply, but margin compression versus the 2021 peak and some cash-flow conversion variability temper the score.
Income Statement
74PositiveBalance Sheet
90Very PositiveCash Flow
71Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.16B | 4.03B | 4.00B | 3.86B | 3.73B | 3.95B |
| Gross Profit | 2.81B | 2.76B | 2.80B | 2.71B | 2.63B | 2.94B |
| EBITDA | 744.61M | 822.72M | 816.80M | 799.05M | 779.84M | 1.12B |
| Net Income | 491.87M | 410.35M | 421.36M | 445.05M | 361.57M | 772.02M |
Balance Sheet | ||||||
| Total Assets | 6.52B | 6.23B | 6.21B | 6.08B | 5.95B | 5.94B |
| Cash, Cash Equivalents and Short-Term Investments | 1.14B | 1.09B | 1.04B | 972.74M | 999.58M | 1.17B |
| Total Debt | 146.46M | 114.45M | 119.28M | 126.62M | 126.91M | 125.38M |
| Total Liabilities | 2.22B | 2.18B | 2.36B | 2.45B | 2.35B | 2.32B |
| Stockholders Equity | 4.31B | 4.05B | 3.85B | 3.63B | 3.60B | 3.62B |
Cash Flow | ||||||
| Free Cash Flow | 602.50M | 490.78M | 622.65M | 608.06M | 276.83M | 771.45M |
| Operating Cash Flow | 749.89M | 593.22M | 738.23M | 785.78M | 568.73M | 1.17B |
| Investing Cash Flow | -296.71M | -112.44M | -254.91M | -195.94M | -213.32M | -563.43M |
| Financing Cash Flow | -307.90M | -464.58M | -355.72M | -598.34M | -501.69M | -458.33M |
Align Tech Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALGN, the sentiment is Neutral. The current price of 163.96 is above the 20-day moving average (MA) of 160.21, above the 50-day MA of 152.02, and below the 200-day MA of 168.69, indicating a neutral trend. The MACD of 4.81 indicates Negative momentum. The RSI at 54.86 is Neutral, neither overbought nor oversold. The STOCH value of 48.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ALGN.
Align Tech Risk Analysis
Align Tech disclosed 37 risk factors in its most recent earnings report. Align Tech reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksAlign Tech Peers Comparison
Overall Rating
GEHC79Outperform
ALGN73Outperform
INMD69Neutral
PHG67Neutral
VREX57Neutral
BFLY54Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 79Outperform | $37.00B | 17.36 | 19.85% | 0.18% | 6.87% | -2.26% | |
| 73Outperform | $11.52B | 23.72 | 11.76% | ― | 4.42% | 33.43% | |
| 69Neutral | $743.47M | 10.47 | 11.36% | ― | 2.50% | -43.86% | |
| 67Neutral | $29.02B | 26.95 | 8.44% | 3.31% | ― | ― | |
| 57Neutral | $768.59M | 34.54 | 4.60% | ― | 5.31% | ― | |
| 54Neutral | $1.54B | -27.72 | -28.22% | ― | 39.35% | 38.09% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ALGN | Align Technology | 163.96 | 31.15 | 23.45% | |
| PHG | Koninklijke Philips N.V. | 29.81 | 3.95 | 15.28% | |
| VREX | Varex Imaging Corporation | 18.15 | 7.86 | 76.38% | |
| INMD | Inmode | 12.88 | -0.86 | -6.26% | |
| BFLY | Butterfly Network, Inc. | 6.08 | 3.76 | 162.07% | |
| GEHC | Ge Healthcare Technologies Inc. | 83.66 | 9.06 | 12.14% |
Align Tech Corporate Events
Align Technology Announces $270 Million Share Repurchase Agreement
PositiveOn November 5, 2026, Align Technology entered an accelerated share repurchase agreement with Goldman Sachs to repurchase $270 million of common stock under its $1.0 billion program approved in April 2025. Align announced the agreement on November 6,...
Align Tech announces CEO succession and leadership transition
PositiveAlign Technology announced on October 28, 2026, that its board has approved a CEO succession under which Jennifer L. Davis will join as CEO-elect and director on November 2, 2026, and become President and CEO on December 31, 2026. Davis, a veteran co...
Align Tech adds Quentin Blackford to board
PositiveOn August 27, 2026, Align Technology’s board appointed Quentin Blackford, president and CEO of iRhythm Technologies, as a director, expanding the board from ten to eleven members and immediately adding a leader with deep experience in global healthca...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026
